What Sparked Serina Therapeutics (SER) 35% After-Hours Surge?

Benzinga_recent_news13:09

Serina Therapeutics Inc. (NYSEAMERICAN: SER) shares jumped 34.93% to $3.67 in after-hours trading on Wednesday after Food and Drug Administration cleared its Investigational New Drug application for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607000774?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/29/Stock-Market-Trading-Graph.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-29 13:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607000774","market":"sh","top_or_hot":-1,"title":"What Sparked Serina Therapeutics (SER) 35% After-Hours Surge?","media":"Benzinga_recent_news","content":"<div>\n<p>Serina Therapeutics Inc. (NYSEAMERICAN: SER) shares jumped 34.93% to $3.67 in after-hours trading on Wednesday after Food and Drug Administration cleared its Investigational New Drug application for ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/01/50215493/what-sparked-serina-therapeutics-ser-35-after-hours-surge\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Sparked Serina Therapeutics (SER) 35% After-Hours Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Sparked Serina Therapeutics (SER) 35% After-Hours Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-29 13:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/26/01/50215493/what-sparked-serina-therapeutics-ser-35-after-hours-surge><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Serina Therapeutics Inc. (NYSEAMERICAN: SER) shares jumped 34.93% to $3.67 in after-hours trading on Wednesday after Food and Drug Administration cleared its Investigational New Drug application for ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/01/50215493/what-sparked-serina-therapeutics-ser-35-after-hours-surge\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4150","symbol_name":"赌场与赌博","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/26/01/50215493/what-sparked-serina-therapeutics-ser-35-after-hours-surge","article_id":"2607000774","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/29/Stock-Market-Trading-Graph.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/01/50215493/what-sparked-serina-therapeutics-ser-35-after-hours-surge","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607000774","pubTimestamp":1769663340,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Serina Therapeutics shares jumped nearly 35% after the FDA cleared its IND application for SER-252, advancing plans for a Phase 1b trial in advanced Parkinson's disease.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4150":"赌场与赌博","BK4139":"生物科技","RSI":"Rush Street Interactive, Inc.","SER":"Serina Therapeutics, Inc."},"translate_title":"是什么引发了Serina Therapeutics(SER)盘后35%的飙升？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SER":1.5,"RSI":1},"content_text":"Serina Therapeutics Inc. (NYSEAMERICAN: SER) shares jumped 34.93% to $3.67 in after-hours trading on Wednesday after Food and Drug Administration cleared its Investigational New Drug application for SER-252, an investigational therapy for advanced Parkinson’s disease.\nBefore the announcement, the stock of the biotechnology company closed regular trading at $2.72, down 0.73%, according to Benzinga Pro data.\nThe company said the IND clearance allows Serina to move forward with regulatory and site-level preparations for a planned Phase 1b registrational clinical trial of SER-252 in patients with advanced Parkinson's disease.\nThe FDA has aligned on a 505(b)(2) New Drug Application pathway for the program, which allows approval for drugs that partly rely on published literature or FDA findings for reference listed drugs.\nSteve Ledger, Chief Executive Officer of Serina Therapeutics, said, \"FDA clearance of the IND is a major milestone for Serina and underscores the promise of the SER-252 program.\"\nSER-252 is developed using Serina’s proprietary POZ Platform, a poly(2-oxazoline)-based polymer technology designed to provide controlled drug release through subcutaneous injection.\nSerina's Relative Strength Index (RSI) stands at 48.36.\nWith a market capitalization of $29.01 million, the stock of the Alabama-based clinical-stage company has a 52-week high of $7.92 and a 52-week low of $1.71.\nSerina has faced a challenging 12 months, with its stock falling 42.98%.\nThe stock is currently trading at about 16.27% of its annual range, placing it closer to its low than its high.\nThe stock's decline and weak positioning suggest that any signs of a recovery would need clear confirmation before investors consider making significant moves.\nBenzinga's Edge Stock Rankings indicate that SER has a negative price trend across all time frames.\nPhoto: Champ008 / Shutterstock\nDisclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607000774","isCrawlerRequest":true}